- the patient population that was included/excluded in the trial
- whether the primary outcome is one that is meaningful (trials of fibrinolytics for complicated parapneumonic effusions are bedeviled by this problem)
- the magnitude of the absolute difference in outcomes (positive utilities)
- the magnitude of the absolute difference in costs, side effects (negative utilities)
Recently I admitted a patient 9 months into a 12 month course of Dual Anti-Platelet Therapy (DAPT) after drug-eluting coronary stent placement. He had bleeding that abated with 12 hours of observation and holding DAPT (ASA 81 mg and clopidogrel/Plavix). The question of course is, do we restart DAPT, and if so when, and what are we losing in terms of the benefit of DAPT during the hiatus?